Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + Gemcitabine + Trilaciclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 12||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Trilaciclib||G1T28||CDK4/6 Inhibitor 10||Trilaciclib (G1T28) is a small molecule that inhibits CDK4/6, resulting in reversible cell-cycle arrest, and potentially reduces myelosuppression induced by chemotherapeutics (PMID: 26826116, PMID: 31575503).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Carboplatin + Gemcitabine + Trilaciclib||Phase II||Actionable||In a Phase II trial, Trilaciclib (G1T28) in combination with Gemzar (gemcitabine) and Paraplatin (carboplatin) were well tolerated in patients with metastatic triple-negative breast cancer, and resulted in an objective response rate of 43% (26/60, all partial responses), a median overall survival of 20.1 months, and a median progression-free survival of 8.8 months, but did not significantly improve myelosuppression (PMID: 31575503; NCT02978716).||31575503|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02978716||Phase II||Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib||Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)||Active, not recruiting||USA||7|